Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution
Seminars in Respiratory and Critical Care Medicine · 2025-08 · 46 (04) · 298-310
DOI: 10.1055/a-2666-7479 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, online erschienen am 19.08.2025. Verfasst von Sean M Fortier und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Scleroderma Foundation.
Abstract (Originalsprache)
Tissue fibrosis contributes to progressive organ dysfunction in a multitude of chronic human diseases. Despite decades of ongoing research dedicated to determining the cellular and molecular origins of fibrosis across multiple organs, we continue to lack truly impactful therapies that halt or reverse scarring. This unmet need is especially evident among individuals with fibrotic lung disease, such as idiopathic pulmonary fibrosis (IPF), who frequently succumb to progressive respiratory failure a few years after diagnosis. Current therapies approved for IPF and progressive fibrotic lung diseases emerged from a longstanding drug development paradigm focused on the inhibition of pro-fibrotic drivers of fibrosis. Given that the vast majority of patients with fibrotic lung disease present with already established scarring, the relative paucity of research focused on fibrosis resolution pathways represents a glaring and critical gap in our knowledge. In contrast to the progressive pathologic fibrosis emblematic of IPF, fibrosis evolved as a self-limited wound-healing response to tissue injury, and spontaneous resolution of lung fibrosis is observed in various experimental animal models. These naturally resolving animal models of fibrosis provide an opportunity to define endogenous anti-fibrotic mediators that inhibit multiple drivers of fibrosis and can orchestrate the return of tissue homeostasis. Therapeutic restoration of these endogenous “resolvers”—which are ostensibly disabled in states of pathologic fibrosis—has immense therapeutic potential. In this perspective, we contend that a paradigm shift in our approach toward fibrosis research is needed. Specifically, we propose that pulmonary fibrosis research be reprioritized to collectively focus on mechanisms of fibrosis resolution using rigorous methods designed to unveil, validate, and explore the therapeutic implications of endogenous resolvers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
- Division of Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado.
Förderung
- NHLBI NIH HHS
- National Scleroderma Foundation
Zitieren
APA
Fortier, S. M., Redente, E. F., & Peters-Golden, M. (2025). Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution. Seminars in Respiratory and Critical Care Medicine, 46(04), 298-310. https://doi.org/10.1055/a-2666-7479
Vancouver
Fortier SM, Redente EF, Peters-Golden M. Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution. Seminars in Respiratory and Critical Care Medicine. 2025;46(04):298-310. doi:10.1055/a-2666-7479
BibTeX
@article{Fortier2025,
author = {Fortier, Sean M and Redente, Elizabeth F and Peters-Golden, Marc},
title = {Reimagining Fibrosis Research, Outcomes, and Therapeutics Through the Lens of Resolution},
journal = {Seminars in Respiratory and Critical Care Medicine},
year = {2025},
volume = {46},
number = {04},
pages = {298--310},
doi = {10.1055/a-2666-7479}
}
EUVIMED